

IDS #2  
9/4/01

Exp. Mail EL852432445		
<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT</b></p> <p>Address to: Commissioner for Patents Washington, D.C. 20231</p>	Attorney Docket	STAN-190
	First Named Inventor	Zeng et al.
	Application Number	Unassigned
	Filing Date	Herewith
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Title	<i>Methods for Inhibition of Polyclonal B Cell Activation and Immunoglobulin Class Switching to Pathogenic Autoantibodies by Blocking CD1-Mediated Interaction.</i>

JC949 U.S. PTO  
09/04/01  
04/27/01

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. '102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 27, 2001

By: Pamela J. Sherwood  
Pamela J. Sherwood  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\STAN (Stanford)\190us1\IDS - before 1st OA1.doc